Last reviewed · How we verify
Spikevax bivalent Original/Omicron BA.1
This bivalent mRNA vaccine encodes spike proteins from both the original SARS-CoV-2 strain and the Omicron BA.1 variant to elicit immune responses against multiple viral variants.
This bivalent mRNA vaccine encodes spike proteins from both the original SARS-CoV-2 strain and the Omicron BA.1 variant to elicit immune responses against multiple viral variants. Used for COVID-19 prevention in adults (booster dose).
At a glance
| Generic name | Spikevax bivalent Original/Omicron BA.1 |
|---|---|
| Sponsor | Jules Bordet Institute |
| Drug class | mRNA vaccine |
| Target | SARS-CoV-2 spike protein (original strain and Omicron BA.1 variant) |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Spikevax bivalent Original/Omicron BA.1 is a messenger RNA vaccine that instructs cells to produce spike proteins from two different SARS-CoV-2 strains simultaneously. This dual-antigen approach aims to broaden immune coverage and improve protection against both ancestral and Omicron BA.1 variant infections. The vaccine triggers both humoral and cellular immune responses through the lipid nanoparticle delivery system.
Approved indications
- COVID-19 prevention in adults (booster dose)
Common side effects
- Injection site pain
- Fatigue
- Headache
- Myalgia
- Fever
- Chills
Key clinical trials
- Bringing Optimised COVID-19 Vaccine Schedules To ImmunoCompromised Populations (BOOST-IC): an Adaptive Randomised Controlled Clinical Trial (PHASE3)
- COVID-19: Immune Response in Patients With Cancer Undergoing mRNA Vaccination Against SARS-CoV-2 (PHASE4)
- COvid-19 Vaccine Booster in Immunocompromised Rheumatic Diseases (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: